Nerve Block of the Vastus Medialis and Anterior Obturator Branch in Anterior Cruciate Ligament Reconstruction With DIDT Graft (RECUP-NVM)
The goal of this randomized clinical trial is to evaluate whether a targeted regional anesthesia strategy combining an adductor canal block, a nerve to the vastus medialis (NVM) block, an anterior obturator nerve branch block, and an iPACK block improves postoperative recovery in patients undergoing anterior cruciate ligament (ACL) reconstruction using a hamstring tendon (semitendinosus and gracilis; DIDT) graft, compared with the standard analgesic protocol used in participating centres, consisting of a femoral nerve block combined with an iPACK block.
The main question the study aims to answer is whether this targeted combination of nerve blocks, compared with the standard femoral nerve block plus iPACK regimen, improves the quality of postoperative recovery, as measured by the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery.
The study hypothesis is that the targeted adductor canal + NVM + anterior obturator branch + iPACK strategy will significantly improve postoperative recovery quality at 24 hours compared with the standard femoral nerve block + iPACK protocol, with an expected improvement of at least 8 points on the QoR-15 score. This 8-point difference represents the minimal clinically important difference (MCID) for this questionnaire (Léger et al., 2020). The QoR-15 is a validated global recovery assessment tool, available in French, and sensitive to variations in recovery quality in outpatient orthopedic surgery (Nakase et al., 2021). An improvement of at least 8 points at 24 hours would therefore indicate a clinically meaningful benefit from the patient's perspective.
The study will also assess:
- Postoperative pain at rest and during mobilization.
- Opioid consumption during the first 48 hours after surgery.
- Incidence of postoperative nausea and vomiting.
- Time to first ambulation.
- Postoperative thigh edema.
- Neuromuscular recovery of the thigh.
- Patient satisfaction with analgesic management.
- Adverse events related to regional anesthesia.
Participants will be randomly assigned to one of two treatment groups. All participants will undergo ACL reconstruction with a DIDT graft. Participants in the comparator group will receive a femoral nerve block combined with an iPACK block. Participants in the intervention group will receive a targeted regional anesthesia strategy combining an adductor canal block, a nerve to the vastus medialis (NVM) block, an anterior branch of the obturator nerve block, and an iPACK block.
The planned volumes and doses for each block in the two randomized strategies are detailed as follows: Compared with the control group, which receives a femoral nerve block with 15 mL and an iPACK block with 20 mL of ropivacaine 0.35% (total volume: 35 mL; total dose: 122.5 mg), the intervention group receives an adductor canal block with 10 mL, a nerve to the vastus medialis block with 5 mL, an anterior branch of the obturator nerve block with 6 mL, and an iPACK block with 20 mL of ropivacaine 0.35% (total volume: 41 mL; total dose: 143.5 mg). Thus, the intervention group involves two additional nerve block targets and an additional 6 mL of ropivacaine, corresponding to an additional dose of 21 mg (+17.1%) compared with the control group. The cumulative dose will be checked against the patient-specific safety limits before performing the blocks. Patients in whom the blocks cannot be safely performed within these limits will not be included.
Postoperative assessments will include pain scores, QoR-15 questionnaires, opioid consumption, nausea and vomiting, thigh measurements, and neuromuscular function assessments during the first 48 hours after surgery. Patient satisfaction and safety outcomes will also be assessed during follow-up.
The primary outcome will compare the QoR-15 score at 24 hours between the two groups, with an 8-point difference considered clinically meaningful.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Yoann ELMALEH
- Numero di telefono: +33 07 81 33 04 31
- Email: yoann.d.elmaleh@gmail.com
Luoghi di studio
-
-
-
Quincy-sous-Sénart, Francia
- Hôpital Privé Claude Galien
-
Contatto:
- Yoan Elmaleh
- Numero di telefono: +33 7 81 33 04 31
- Email: yoann.d.elmaleh@gmail.com
-
Évry, Francia
- Clinique du Mousseau
-
Contatto:
- Karim Guessous
- Numero di telefono: +33 6 51 99 54 38
- Email: k.guessous@quincyanesthesie.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adult patients aged 18 to 60 years.
- Patients with a primary anterior cruciate ligament (ACL) injury.
- Patients scheduled for ACL reconstruction using a DIDT graft under general anesthesia.
- Patients managed as ambulatory surgery or short stay.
- Patients who understand the validated French version of the QoR-15 questionnaire.
- Patients who have given written informed consent to participate in the study.
- Patients affiliated with or beneficiaries of a social security system.
Exclusion Criteria:
- Patients with a body weight below 50 kg, as the planned cumulative ropivacaine dose could exceed the safety limit of 3 mg/kg.
- Patients with allergy to local anesthetics or a contraindication to peripheral nerve blocks.
- Patients with lower-limb neuropathy.
- Patients with coagulation disorders or on major anticoagulation.
- Patients with chronic pain requiring more than 30 mg morphine-equivalents per day.
- Patients undergoing revision ACL reconstruction or a major combined surgical procedure.
- Pregnant women.
- Patients unable to complete the questionnaires or who refuse to participate.
- Pregnant women or women who may be pregnant (of childbearing potential without effective contraception) or who are breastfeeding.
- Protected adults: patients under guardianship, curatorship or other legal protection, deprived of liberty, or unable to provide informed consent.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Adductor Canal + iPACK + NVM and Anterior Obturator Nerve Blocks
Participants will undergo anterior cruciate ligament reconstruction using a semitendinosus and gracilis (DIDT) graft. They will receive a targeted regional anesthesia protocol consisting of an adductor canal block, a nerve to the vastus medialis (NVM) block, an iPACK block, and a block of the anterior branch of the obturator nerve. |
Ultrasound-guided infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) administered as part of the regional anesthesia protocol. Ultrasound-guided nerve block targeting the nerve to the vastus medialis (NVM), administered in addition to theadductor canal and iPACK blocks in the experimental arm. Ultrasound-guided block of the anterior branch of the obturator nerve, administered in addition to the adductor canal and iPACK blocks in the experimental arm. Ultrasound-guided adductor canal block administered as part of the targeted regional anesthesia protocol for ACL reconstruction in the experimental arm. |
|
Comparatore attivo: Femoral + iPACK Nerve Blocks
Participants will undergo anterior cruciate ligament reconstruction using a semitendinosus and gracilis (DIDT) graft. They will receive the standard regional anesthesia protocol consisting of a femoral nerve block and an iPACK block, without additional nerve blocks of the nerve to the vastus medialis (NVM) or anterior branch of the obturator nerve. |
Ultrasound-guided infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) administered as part of the regional anesthesia protocol. Ultrasound-guided femoral nerve block administered as part of the standard regional anesthesia protocol for ACL reconstruction. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Quality of Recovery (QoR-15) Score
Lasso di tempo: Baseline (preoperatively, before regional anesthesia) and 24 hours after surgery
|
The quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 score ranges from 0 to 150, with higher scores indicating better quality of recovery. The primary analysis will compare the change in QoR-15 score from baseline to 24 hours postoperatively between the experimental and active comparator groups. An 8-point difference between groups is considered the minimal clinically important difference. |
Baseline (preoperatively, before regional anesthesia) and 24 hours after surgery
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Postoperative Pain
Lasso di tempo: 6, 24, and 48 hours after surgery
|
Pain intensity will be assessed using the Numeric Rating Scale (NRS), both at rest and during mobilization. The NRS ranges from 0 (no pain) to 10 (worst pain imaginable). |
6, 24, and 48 hours after surgery
|
|
Postoperative Opioid Consumption
Lasso di tempo: 24 and 48 hours after surgery
|
Total opioid consumption will be recorded and converted to oral morphine equivalents (OME). |
24 and 48 hours after surgery
|
|
Postoperative Nausea and Vomiting
Lasso di tempo: 24 and 48 hours after surgery
|
The incidence of postoperative nausea and vomiting (PONV) will be recorded. |
24 and 48 hours after surgery
|
|
Time to ambulation
Lasso di tempo: Day 0 (postoperative)
|
Time from completion of surgery to first postoperative ambulation will be recorded. |
Day 0 (postoperative)
|
|
Postoperative Thigh Edema
Lasso di tempo: Day 0 and Day 1 after surgery
|
Postoperative changes in thigh circumference will be measured at three standardized locations: 15 cm above the superior pole of the patella, at the level of the patellar apex, and 10 cm below the patellar apex. |
Day 0 and Day 1 after surgery
|
|
Postoperative Neuromuscular Recovery of the Thigh
Lasso di tempo: Day 0 and Day 1 after surgery
|
Neuromuscular recovery will be assessed using the Medical Research Council (MRC) scale, ranging from 0 (no muscle contraction) to 5 (normal muscle strength), across four motor tests: isometric heel press into the mattress, flattening of the popliteal fossa against the mattress, sliding knee flexion/extension, and straight-leg raise at 30 degrees. |
Day 0 and Day 1 after surgery
|
|
Adverse Events Related to Regional Anesthesia
Lasso di tempo: Day 0
|
Adverse events related to locoregional anesthesia will be recorded, including signs of local anesthetic systemic toxicity (LAST) and persistent paresthesia. |
Day 0
|
|
Patient Satisfaction With Analgesic Management
Lasso di tempo: 1 month after surgery
|
Patient satisfaction with postoperative analgesic management will be assessed using a 5-point Likert scale ranging from 1 (Very dissatisfied) to 5 (Very satisfied). Higher scores indicate greater patient satisfaction and a better outcome. |
1 month after surgery
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Yoann ELMALEH, Hôpital Privé Claude Galien
Pubblicazioni e link utili
Pubblicazioni generali
- Leger M, Campfort M, Cayla C, Parot-Schinkel E, Lasocki S, Rineau E. Validation of an alternative French version of the Quality of Recovery-15 Score: the FQoR-15. Br J Anaesth. 2020 Oct;125(4):e345-e347. doi: 10.1016/j.bja.2020.05.052. Epub 2020 Jul 9. No abstract available.
- Myles PS, Myles DB, Galagher W, Chew C, MacDonald N, Dennis A. Minimal Clinically Important Difference for Three Quality of Recovery Scales. Anesthesiology. 2016 Jul;125(1):39-45. doi: 10.1097/ALN.0000000000001158.
- Demumieux F, Ludes PO, Diemunsch P, Bennett-Guerrero E, Lujic M, Lefebvre F, Noll E. Validation of the translated Quality of Recovery-15 questionnaire in a French-speaking population. Br J Anaesth. 2020 Jun;124(6):761-767. doi: 10.1016/j.bja.2020.03.011. Epub 2020 Apr 15.
- Nakase J, Shimozaki K, Asai K, Yoshimizu R, Kimura M, Tsuchiya H. Usefulness of lateral femoral cutaneous nerve block in combination with femoral nerve block for anterior cruciate ligament reconstruction: a prospective trial. Arch Orthop Trauma Surg. 2021 Mar;141(3):455-460. doi: 10.1007/s00402-020-03724-9. Epub 2021 Jan 2.
- Le Bescond V, Petit-Phan J, Campfort M, Nicolleau C, Conte M, Bouhours G, Rony L, Lasocki S, Leger M. Validation of the postoperative Quality of Recovery-15 questionnaire after emergency surgery and association with quality of life at three months. Can J Anaesth. 2024 May;71(5):590-599. doi: 10.1007/s12630-024-02722-4. Epub 2024 Mar 19.
- Uddin I, Chazapis M. Obturator nerve block [Internet]. World Federation of Societies of Anaesthesiologists; juin 2024 [cité 4 févr 2026]. https://resources.wfsahq.org/atotw/obturator-nerve-block/ doi:10.28923/atotw.525
- Savalli L, Hernandez-Sendin MI, Puig PL, Trouve P. [Pain after anterior cruciate ligament reconstruction: detail and treatment]. Ann Readapt Med Phys. 2004 Aug;47(6):299-308. doi: 10.1016/j.annrmp.2004.05.005. French.
- Kim KY, Huh YG, Ma SH, Yoon JH, Jeong KY, Park DY, Yoon SH. Efficacy of Adductor Canal Block on Medial Knee Pain in Patients with Knee Osteoarthritis: A Randomized Single-Blind Placebo-Controlled Study. Int J Environ Res Public Health. 2022 Nov 21;19(22):15419. doi: 10.3390/ijerph192215419.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- COS-RGDS-2025-12-028-P-ELMALEH
- 2026-A01040-51 (Altro identificatore: ID-RCB)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .